New Zealand markets closed

OCGN Jan 2024 3.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.2200+0.0100 (+4.76%)
As of 12:12PM EST. Market open.
Full screen
Previous close0.2100
Open0.2500
Bid0.1800
Ask0.2600
Strike3.50
Expiry date2024-01-19
Day's range0.2200 - 0.2500
Contract rangeN/A
Volume2
Open interest20
  • Motley Fool

    1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell

    Ocugen (NASDAQ: OCGN) soared into the spotlight -- and its stock soared too -- when it entered the COVID-19 vaccine race two years ago. Or has Ocugen left center stage for good? Let's consider one reason to buy Ocugen in 2023 -- and two reasons to sell.

  • GlobeNewswire

    Ocugen Appoints Quan A. Vu as Chief Business Officer

    MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline. “Expanding Ocugen’s product portfolio and capabilities, in line w

  • GlobeNewswire

    Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

    MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Dr. Musunuri and members of Ocugen’s executive tea